Table II.
Details of further studies done on OBI samples.
| Sample | NAT reactive at dilution | Anti-HBcAg (IgG+IgM) | Anti-HBcAg (IgM) | Anti-HBsAg | Viral load (IU/mL) | Genotype | Percentage of total NAT yield | Donor demographic details | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Age | Type | ||||||||
| Samples reactive at dilution <1:4 | |||||||||
|
| |||||||||
| 1 | 1 | NR | NR | NR | ND | ND | 22.22% | 29 | RD |
| 2 | 1 | NR | NR | NR | ND | ND | 23 | RD | |
| 3 | 1 | NR | NR | NR | 38 | ND | 23 | RD | |
| 4 | 1 | NR | NR | R | <10 | ND | 32 | VD | |
|
| |||||||||
| 5 | 1 | R | NR | R | ND | ND | 27.77% | 40 | VD |
| 6 | 1 | R | NR | NR | <10 | ND | 28 | RD | |
| 7 | 1 | R | NR | NR | 13 | ND | 48 | VD | |
| 8 | 1 | R | NR | NR | 38 | ND | 29 | RD | |
| 9 | 2 | R | NR | NR | 22 | ND | 30 | VD | |
|
| |||||||||
| Samples reactive at dilution ≥1:4 | |||||||||
|
| |||||||||
| 10 | 8 | NR | NR | NR | 16 | ND | 11.11% | 21 | RD |
| 11 | 4 | NR | NR | NR | 505 | ND | 27 | VD | |
|
| |||||||||
| 12 | 8 | R | R | NR | 38 | ND | 38.88% | 19 | RD |
| 13 | 4 | R | NR | R | 115 | ND | 22 | RD | |
| 14 | 8 | R | NR | NR | 2,711 | ND | 20 | RD | |
| 15 | 16 | R | NR | R | 15,849 | A | 32 | RD | |
| 16 | 16 | R | NR | NR | 177,827,941 | A | 21 | RD | |
| 17 | 16 | R | NR | NR | 154,881,662 | A | 22 | RD | |
| 18 | 16 | R | NR | NR | 5,011,872 | A | 30 | VD | |
OBI: occult hepatitis B infection; NAT: nucleic acid testing; HBcAg: hepatitis B virus core antigen; IgG: immunoglobulin G; IgM: immunoglobulin M; HBsAg: hepatitis B virus surface antigen; R: reactive; NR: non-reactive; ND: not determined.